) -

"Immunologic functions of human alveolar cells" NAME OF PRINCIPAL INVESTIGATOR Robert A. Goldstein, M.D. 1. This is to certify that the grant application entitled "Immuno of human alveolar cells" (Ptoposal, application, procedure, drug usage, si identified above has been reviewed by the Research and Education Subcommittee to consider clinical research proposals and other investigations involving human be to consider clinical research proposals and other investigations involving human be to consider clinical research proposals and other investigations involving human be to consider clinical research proposals and other investigations involving human be to consider clinical research proposals and other investigations involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (s) or (b)) [A) (a) the proposed drug usages and/or procedures are considered approval is not recommended for the reasons stated in the attached to the proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Macket of the proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Macket of the proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Macket of the proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Macket of the proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Macket of the proposal is not recommended for the reasons stated in the attached to the proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Macket of the proposal is not recommended for the reasons stated in the attached to the proposal is not recommended for the reasons stated in the attached to the proposal is not recommended for the reasons stated in the attached to the proposal is not recommended for the reasons stated in the attached to the proposal is not recommended for the propos	
Robert A. Goldstein, M.D. 1. This is to certify that the grant application entitled "Immuno of human alveolar cells" (Proposal, application, procedure, drug usage, si identified above has been reviewed by the Rescarch and Education Subcommittee to consider clinical research proposals and other investigations involving human been as the subcommittee on Human Studies has considered specifically: (a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered approval is not recommended for the reasons stated in the attached. (b) the proposed drug usages and/or procedures are considered inappropriate approval is not recommended for the reasons stated in the attached. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
1. This is to certify that the grant application entitled "Immuno of human alveolar cells" (Proposal, application, procedure, drug usage, si identified above has been reviewed by the Research and Education Subcommittee to consider clinical research proposals and other investigations involving human be considered investigations involving human be grant to the rights and welfare of the individual(s) involved. (a) the rights and welfare of the individual(s) involved. (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered approached in the proposed drug usages and/or procedures are considered inapproapproval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M	NC
of human alveolar cells" (Proposal, epplication, procedure, drug usage, si identified above has been reviewed by the Research and Education Subcommittee of to consider clinical research proposals and other investigations involving human between the considered specifically: (a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Man	C.
of human alveolar cells" (Proposal, epplication, procedure, drug usage, si identified above has been reviewed by the Research and Education Subcommittee of to consider clinical research proposals and other investigations involving human between the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappr approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M	
of human alveolar cells" (Proposal, epplication, procedure, drug usage, si identified above has been reviewed by the Research and Education Subcommittee of to consider clinical research proposals and other investigations involving human between the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappr approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M	
identified above has been reviewed by the Research and Education Subcommittee to consider clinical research proposals and other investigations involving human be 2. The Subcommittee on Human Studies has considered specifically: (a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappr approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M	
2. The Subcommittee on Human Studies has considered specifically: (a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (b) the proposed drug usages and/or procedures are considered approached. (b) the proposed drug usages and/or procedures are considered inapproached is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
to consider clinical research proposals and other investigations involving human be 2. The Subcommittee on Human Studies has considered specifically: (a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered approximended. (b) the proposed drug usages and/or procedures are considered inapproximended is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
(a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappropriate approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
(a) the rights and welfare of the individual(s) involved, (b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappropriate approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
(b) the appropriateness of the methods to be used to secure informed consent (c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Gheck (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappropriately approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
(c) the risks and potential medical benefits of the investigation. 3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inappropriately approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	
3. The collective judgment of the Subcommittee is that: (Check (a) or (b)) (a) the proposed drug usages and/or procedures are considered ap recommended. (b) the proposed drug usages and/or procedures are considered inapproapproval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	, and
(a) the proposed drug usages and/or procedures are considered approached. (b) the proposed drug usages and/or procedures are considered inapproached approval is not recommended for the reasons stated in the attached. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M.	•
(b) the proposed drug usages and/or procedures are considered inappropriate approval is not recommended for the reasons stated in the attached. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual M	
approval is not recommended for the reasons stated in the attached. 4. This proposal is consistent with the policy set forth in Chapter 8, DM&S Manual Manu	propriate, and approval is
DATE OF SUBCOMMITTEE ACTION SIGNATURE of Prime Subcormittee of Human Sturies A	<u> </u>
DATE OF SUBCOMMITTEE ACTION SIGNATURE of for Subcormittee of Human Studies	53959
DATE OF SUBCOMMITTEE ACTION SIGNATURE of formation Studies	Ŭ,
DATE OF SUBCOMMITTEE ACTION SIGNATURE of forman Studies	ဖ
DATE OF SUBCOMMITTEE ACTION SIGNATURE of Prihr Subcommittee of Human Stuffe A	
Well was the state of the state	
4/9/73 WILLIAM MCFARLAND, M.D.	in yell
APPROVED 5/3/73 UR W TANTOKT DE D.	ON COMMITTEE
B.W. JANICKI, Ph.D.	*
DISAPPROVED	